Clinical characteristics and outcomes of primary intracranial alveolar soft-part sarcoma: A case report

Table 1 Fourteen cases from previous literature and our institute

Ref.	Sex/age	Location/diameter	Treatment strategies	Salvage treatments and outcomes
Bots et al[9], 1988	M/9 yr	Pituitary gland	NGTR + RT (45 Gy)	Metastases (12.3 mo, GTR); alive (40 mo)
Bodi et al[3], 2009	F/39 yr	L temporal/6 cm	GTR	Tumor free; NED (10 mo)
Das et al[10], 2012	F/17 yr	Bifrontal	GTR + RT	Tumor free; NED (4 mo)
Mandal et al[11], 2013	F/32 yr	R parietal	GTR
Ahn et al[12], 2014	F/9 yr	R CPA/4.5 cm	NGTR + RT (54 Gy)	LR (14 mo, NGTR + GKS + CMT1); alive (56 mo)
Emmez et al[13], 2015	F/11 yr	L frontal	GTR + RT (54 Gy) + CMT2	LR (45 mo, GTR + chemotherapy); alive (54 mo)
Tao et al[15], 2016	F/28 yr	L frontal/4.1 cm	GTR + RT	Tumor free; alive (27 mo)
Tao et al[19], 2017	M/13 yr	R temporal/3.7 cm	NGTR + RT	LR (14 mo); DOD (24 mo)
Kumar et al[14], 2019	M/21 yr	L post. fossa	GTR	Tumor free; NED (8 mo)
Present	M/24 yr	R frontal/3.5 cm	GTR + RT (52 Gy)	Tumor free; NED (25 mo)
Present	F/53 yr	Ant. skull base/5.0 cm	NGTR + RT (46 Gy) + CMT3	LR (10 mo, surg.); AWD (36 mo)
Present	M/21 yr	R parietooccipital/4.0 cm	GTR	Metastases (15 mo); DOD (26 mo)
Present	F/8 yr	R temporal/2.8 cm	NGTR + RT	LR (8 mo, surg.); DOD (50 mo)
Present	F/16 yr	L parietal/3.0 cm	GTR + RT (42 Gy)	LR (32 mo, surg. + CMT1 + RT); DOD (61 mo)

¹CMT, ifosfamide, carboplatin, and etoposide.

²CMT, ifosfamide, vincristine, and actinomycin.

³CMT, doxorubicin and ifosfamide.

M: Male; F: Female; R: Right; L: Left; GTR: Gross total resection; NGTR: Non-gross total resection; RT: Radiotherapy; GKS: Gamma knife surgery; CMT: Chemotherapy; NED: No evidence of disease; DOD: Dead of disease; LR: Local recurrence.